Ultrasound tissue characterization by integrated backscatter for analyzing fluorouracil induced myocardial damage

Echocardiography

Volumn 22, Issue 3, 2005, Pages 233-238

  Ceyhan, Ceyhun ^a   Meydan, Nezih ^a   Barutca, Sabri ^a   Tekten, Tarkan ^a   Onbasili, Alper O ^a   Ozturk, Banu ^a   Unal, Selim ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

5 fluorouracil; Cardiotoxicity; Integrated backscatter

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG INFUSION; DRUG MEGADOSE; FEMALE; HEART LEFT VENTRICLE WALL; HEART MUSCLE INJURY; HEART VENTRICLE SEPTUM; HUMAN; M MODE ECHOCARDIOGRAPHY; MALE; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ACOUSTICS; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DENSITOMETRY; ECHOCARDIOGRAPHY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEART; HEART SEPTUM; HEART VENTRICLES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PROSPECTIVE STUDIES; SCATTERING, RADIATION;

EID: 14844328720     PISSN: 07422822     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0742-2822.2005.03169.x     Document Type: Article

References (37)

1. Labianca R, Beretta G, Clerici M, et al: Cardiac toxicity of 5-fluorouracil: A study on 1083 patients. Tumori 1982;68:505-510.
2. Schober C, Papageorgiou E, Harstrick A, et al: Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993;72:2242-2247.
3. de Forni M, Malet-Martino MC, Jaillais P, et al: Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study. J Clin Oncol 1992;10:1795-1801.
4. Meyer CC, Calis KA, Burke LB, et al: Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997;17:729-736.
5. Eskilsson J, Albertsson M, Mercke C: Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 1988;13:41-46.
6. Gradishar WJ, Vokes EE: 5-Fluorouracil carditoxicity: A critical review. Ann Oncol 1990;1:409-414.
7. Robben NC, Pippas AW, Moore JO: The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993;71:493-509.
8. Lemaire L, Malet-Martino MC, de Forni M, et al: Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 1992;1:119-127.
9. Arellano M, Malet-Martino M, Martino R, et al: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 1998;1:79-86.
10. Cwikiel M, Persson SU, Larsson H, et al: Changes of blood viscosity in patients treated with 5-fluorouracil - a link to cardiotoxicity? Acta Oncol 1995;34:83-85.
11. Patel B, Kloner RA, Ensley J, et al: 5-fluorouracil cardiotoxicity: Left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238-243.
12. Rezkalla S, Kloner RA, Ensley J, et al: Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study. J Clin Oncol 1989;7:509-514.
13. Thyss A, Falewee MN, Leborgne L, et al: Cardiotoxicity of 5-fluorouracil. Spasm or direct myocardial toxicity? Bull Cancer 1987;74:381-385.
14. Grandi AM, Pinotti G, Morandi E, et al: Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: A one-year follow-up study. Ann Oncol 1997;8:705-708.
15. Mimbs JW, O'Dennel M, Brauwen D, et al: The dependence of ultrasonic attenuation and backscatter on collagen content in dog and rabbit heart. Circ Res 1980;47:48-58.
16. Wickline SA, Thomas LJ III, Miller JG, et al: Sensitive detection of the effects of reperfusion on myocardium by ultrasonic tissue characterization with integrated backscatter. Circulation 1986;74:389-400.
17. Sagar KB, Rhyne TL, Warltier DC, et al: Intramyocardial variability in integrated backscatter: Effects of coronary occlusion and reperfusion. Circulation 1987;75:436-442.
18. Fitzgerald PJ, McDaniel MD, Rolett EL, et al: Two dimensional ultrasonic tissue characterization: Backscatter power, endocardial wall motion, and their phase relationship for normal, ischemic and infracted myocardium. Circulation 1987;76:850-859.
19. Milunski MR, Mohr GA, Perez JE, et al: Ultrasonic tissue characterization with integrated backscatter: Acute myocardial ischemia, reperfusion, and stunned myocardium in patients. Circulation 1989;80:491-503.
20. Vered Z, Barzilai B, Mohr GA, et al: Quantitative ultrasonic tissue characterization with real time integrated backscatter imaging in normal human subjects and in patients with dilated cardiomyopathy. Circulation 1987;76:1067-1073.
21. Masuyama T, St Goar FG, Tye TL, et al: Ultrasonic tissue characterization of human hypertrophied hearts in vivo with cardiac cycle dependent variation of integrated backscatter. Circulation 1989;80:925-934.
22. Lattanzi F, Spirito P, Picano E, et al: Quantitative assessment of ultrasonic myocardial reflectivity in hypertrophic cardiomyopathy. J Am Coll Cardiol 1991;17:1085-1090.
23. Naito J, Masuyama T, Tanouchi J, et al: Analysis of transmural trend of myocardial integrated ultrasound backscatter for differentiation of hypertrophic cardiomyopathy and ventricular hypertrophy due to hypertension. J Am Coll Cardiol 1994;24:517-524.
24. Sagar KB, Pele LE, Rhyne TL, et al: Influence of heart rate, preload, afterload and inotropic state on myocardial ultrasonic backscatter. Circulation 1988;77:478-483.
25. Tekten T, Onbasili AO, Ceyhan C, et al: Cyclic variation of myocardial integrated backscatter and myocardial wall thickness during percutaneous coronary angioplasty. Echocardiography 2003;20:423-428.
26. Goens MB, Karr SS, Martin GR: Cyclic variation of integrated ultrasound backscatter: Normal and abnormal myocardial patterns in children. J Am Soc Echocardiogr 1996;9:616-621.
27. Perez JE, McGill JB, Santiago JV, et al: Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992;19:1154-1162.
28. Yokoyama N, Takeshita S, Kozuma K, et al: Early detection of doxorubicin-induced myocardial damage by ultrasound tissue characterization with integrated backscatter. Circ J 2003;67:929-933.
29. Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantization of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-367.
30. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808-815.
31. Nagai H, Omi W, Yuasa T, et al: Ultrasonic analysis of anthracycline-induced myocardial damage using cyclic variation of integrated backscatter. J Am Soc Echocardiogr 2003;16:808-813.
32. Barutca S, Ceyhan C, Meydan N, et al: A new perspective on cardiotoxicity of 5-fluorouracil: A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen. Chemotherapy 2004;50:113-118.
33. Wickline SA, Thomas LJ III, Miller JG, et al: The dependence of myocardial ultrasonic integrated backscatter on contractile performance. Circulation 1985;72:183-192.
34. Vitale DF, Bonow RO, Gerundo G, et al: Alterations in ultrasonic backscatter during exercise-induced myocardial ischemia in humans. Circulation 1995;92:1452-1457.
35. Robben NC, Pippas AW, Moore JO: The syndrome of 5-fluorouracil cardiotoxicity: An elusive cardiopathy. Cancer 1993;71:493-509.
36. Mimbs JW, Bauwens D, Cohen RD, et al: Effects myocardial ischemia on quantitative ultrasonic backscatter and identification of responsible determinants. Circ Res 1981;49:89-96.
37. Hoffmeister BK, Handley SM, Wickline SA, et al: Ultrasonic integrated backscatter of Young's modulus of fixed tendon and fixed myocardium. J Acoust Soc Am 1996;100:3933-3940.